NO20060561L - Peparater inneholdende sertoliceller og myoidceller og anvendelse av disse i celletransplantater - Google Patents

Peparater inneholdende sertoliceller og myoidceller og anvendelse av disse i celletransplantater

Info

Publication number
NO20060561L
NO20060561L NO20060561A NO20060561A NO20060561L NO 20060561 L NO20060561 L NO 20060561L NO 20060561 A NO20060561 A NO 20060561A NO 20060561 A NO20060561 A NO 20060561A NO 20060561 L NO20060561 L NO 20060561L
Authority
NO
Norway
Prior art keywords
cells
myoid
compositions containing
sertolic
cell grafts
Prior art date
Application number
NO20060561A
Other languages
English (en)
Other versions
NO338745B1 (no
Inventor
Alfred V Vasconcellos
Jannette Dufour
Richelle Hemendinger
Ray V Rajotte
Craigh Halberstadt
Paul Gores
Dwaine Emerich
Greg Korbutt
Original Assignee
Greg Korbutt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greg Korbutt filed Critical Greg Korbutt
Publication of NO20060561L publication Critical patent/NO20060561L/no
Publication of NO338745B1 publication Critical patent/NO338745B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Foreliggende oppfinnelse gjelder anvendelse av sertoli-celler og myoide celler for dannelse av et immunologisk privilegert sete i et pattedyr, slik at transplantasjon av celler som danner en biologisk faktor ved behandling av en sykdom som skyldes mangel på en slik biologisk faktor lettes. Farmasøytiske preparater som inneholder sertoli-celler og myoide celler samt terapeutiske fremgangsmåter som gjelder anvendelse av disse cellene tilveiebringes av foreliggende oppfinnelse.
NO20060561A 2003-07-03 2006-02-03 Farmasøytiske sammensetninger som omfatter sertoliceller og myoidceller og anvendelse av disse i celletransplantater. NO338745B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48496003P 2003-07-03 2003-07-03
PCT/US2004/021462 WO2005018540A2 (en) 2003-07-03 2004-07-02 Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants

Publications (2)

Publication Number Publication Date
NO20060561L true NO20060561L (no) 2006-02-03
NO338745B1 NO338745B1 (no) 2016-10-17

Family

ID=34215816

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060561A NO338745B1 (no) 2003-07-03 2006-02-03 Farmasøytiske sammensetninger som omfatter sertoliceller og myoidceller og anvendelse av disse i celletransplantater.

Country Status (7)

Country Link
US (2) US20050118145A1 (no)
EP (1) EP1648380B1 (no)
JP (1) JP4926703B2 (no)
AU (1) AU2004266126B8 (no)
CA (2) CA2531022C (no)
NO (1) NO338745B1 (no)
WO (1) WO2005018540A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399751B2 (en) 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
CA2531022C (en) * 2003-07-03 2014-09-09 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
WO2007089572A2 (en) * 2006-01-26 2007-08-09 John Constance M Proliferative primary human sertoli cell cultures and their applications
EP2046351A2 (en) * 2006-07-28 2009-04-15 Sertocell Biotechnology (US) Corp. Adult sertoli cells and uses thereof
PL2470228T3 (pl) 2009-08-28 2018-03-30 Sernova Corporation Sposoby i urządzenia do przeszczepiania komórek
KR101986830B1 (ko) 2017-09-07 2019-06-07 차의과학대학교 산학협력단 줄기세포 유래 세르톨리유사세포, 그 제조방법, 및 그의 용도

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
EP0755258B1 (en) * 1994-04-13 2002-01-23 Research Corporation Technologies, Inc Methods of treating disease using sertoli cells and allografts or xenografts
US5958404A (en) * 1994-04-13 1999-09-28 Research Corporation Technologies, Inc. Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
ZA961018B (en) * 1995-02-08 1997-08-08 Yamanouchi Europ Bv Oral dosage-forms containing a beta-lactam antibiotic.
US5830460A (en) * 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
WO1996033264A1 (en) * 1995-04-20 1996-10-24 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
US6036951A (en) * 1996-03-12 2000-03-14 University Of South Florida Sertoli cells as neurorecovery inducing cells for neurodegenerative disorders
US5969211A (en) * 1996-04-19 1999-10-19 Ther Regents Of The University Of California Pantropic retroviral vectors for gene transfer in mollusks
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US20020065212A1 (en) * 1996-11-08 2002-05-30 Selawry Helena P. Methods of treating disease using sertoli cells and allografts or xenografts
AU8679498A (en) * 1997-08-05 1999-03-01 Joslin Diabetes Center Inc. Immunologically privileged cells and uses thereof
US6734338B1 (en) * 1997-11-14 2004-05-11 Cedars-Sinai Medical Center Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
US7294755B1 (en) * 1997-11-14 2007-11-13 Cedars-Sinai Medical Center Genetic modification of male germ cells for generation of transgenic species and genetic therapies
US6316692B1 (en) * 1997-11-14 2001-11-13 Cedars Sinai Medical Center Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
SI20847B (sl) * 1998-12-15 2009-04-30 Univ Mexico Nacional Autonoma Postopek in naprava za zaščito biološkega vsadka
US6303355B1 (en) * 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) * 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6790441B1 (en) * 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
WO2002032437A1 (en) * 2000-10-17 2002-04-25 Diatranz Limited Preparation and xenotransplantation or porcine islets
JP4866535B2 (ja) * 2001-05-11 2012-02-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 動物で用いるに適した免疫調節用デバイス
WO2003027270A1 (en) * 2001-09-28 2003-04-03 Diabcell Pty Limited Growing xenotransplant material in culture
CA2476214A1 (en) * 2002-02-08 2003-08-14 University Of South Florida Proliferated cell lines and uses thereof
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
US20040156878A1 (en) * 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
US20040197374A1 (en) * 2003-04-02 2004-10-07 Alireza Rezania Implantable pouch seeded with insulin-producing cells to treat diabetes
US20040197375A1 (en) * 2003-04-02 2004-10-07 Alireza Rezania Composite scaffolds seeded with mammalian cells
CA2531022C (en) * 2003-07-03 2014-09-09 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
US7625581B2 (en) * 2003-12-19 2009-12-01 Ethicon, Inc. Tissue scaffolds for use in muscoloskeletal repairs
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
EP2046351A2 (en) * 2006-07-28 2009-04-15 Sertocell Biotechnology (US) Corp. Adult sertoli cells and uses thereof

Also Published As

Publication number Publication date
AU2004266126A1 (en) 2005-03-03
WO2005018540A3 (en) 2006-08-24
AU2004266126B8 (en) 2011-07-28
WO2005018540A2 (en) 2005-03-03
EP1648380A4 (en) 2009-12-02
CA2531022C (en) 2014-09-09
EP1648380B1 (en) 2015-04-08
CA2531022A1 (en) 2005-03-03
NO338745B1 (no) 2016-10-17
CA2848954A1 (en) 2005-03-03
JP4926703B2 (ja) 2012-05-09
AU2004266126B2 (en) 2011-06-09
JP2007530416A (ja) 2007-11-01
US20090162331A1 (en) 2009-06-25
EP1648380A2 (en) 2006-04-26
US20050118145A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
AR123811A2 (es) Composiciones de células madre mesenquimáticas purificadas y métodos relacionados
ATE491454T1 (de) Verwendung von pyrrolo-pyrazinderivaten zur behandlung der zystischen fibrose
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
NO20060561L (no) Peparater inneholdende sertoliceller og myoidceller og anvendelse av disse i celletransplantater
NO20051030L (no) Funksjonelle kardiomyocytter fra humane embryonale stamceller
EA200601231A1 (ru) Дефинитивная энтодерма
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20060360L (no) Nye 8-azabisyklo [3.2.1] oktanderivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20084396L (no) Kombinasjonsterapi
EA200601995A1 (ru) Pdx1-экспрессирующая энтодерма
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
DE60230327D1 (de) Polymorphe von clopidogrel-hydrogensulfat
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NO20074207L (no) Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
NO20054769L (no) Substituerte fenylalkansyrer
RU2009138327A (ru) Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees